Swara V.
Class of 2025Cary, North Carolina
About
Projects
- "Safety and efficacy of Allogeneic CAR-T cell for relapsed and refractory Multiple Myeloma" with mentor Carlos (Aug. 2, 2024)
Swara's Symposium Presentation
Project Portfolio
Safety and efficacy of Allogeneic CAR-T cell for relapsed and refractory Multiple Myeloma
Started Mar. 1, 2024
Abstract or project description
Multiple Myeloma (MM) is a rare cancer disease that originates from a plasma cell, a type of immune cell. Currently, there are not many treatments to cure MM. However, chimeric antigen receptor therapy (CAR-T cell therapy) is an emerging cancer immunotherapy used to effectively treat various cancers, including MM. In this article, I compared the efficacy and safety of autologous versus allogeneic CAR-T cell therapy in treating relapsed and refractory multiple myeloma (RRMM), a stage of multiple myeloma where the cancer has returned (relapsed and is resistant (refractory) to the standard treatment. We evaluated clinical outcomes such as response and survival rates, and side-effects of both therapies. Our findings indicate that while both autologous and allogeneic CAR-T cell therapies show potential in managing RRMM, differences in efficacy and safety profiles exist.